BrightPath Biotherapeutics Co., Ltd.
ブライトパス・バイオ株式会社
Valuation
Fundamental ratios for the latest reported period.
Ticker: 4594
FY2025 · 2026-03-31
| Gross margin | 64.3% |
| Operating margin | -1541667.9% |
| Net margin | -1553513.1% |
| Return on equity | — |
| Return on assets | -50.1% |
| Revenue growth (YoY) | -92.6% |
| EPS (basic) | ¥-11.7 |
| EPS growth (YoY) | — |
| Current ratio | 15.83x |
| Equity ratio | 90.1% |
| Book value / share | ¥16.91 |
| Free cash flow | -1,366 M |